दवा संदर्भ
Empagliflozin-linagliptin-metformin
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- दवा वर्ग: Gastrointestinal Tract
- उपयोग: diabetes mellitus
अंतिम अपडेट
केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।
इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।
मुख्य तथ्य
- दवा वर्ग
- Gastrointestinal Tract
- सामान्य रूप
- टैबलेट
- सामान्य मात्राएँ
- 1000 mg
- ब्रांड नाम
- 7
- देश और बाज़ार
- 2
उपयोग
यह कैसे काम करती है
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
वयस्कों की सामान्य खुराक (लेबल सारांश)
Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
गर्भावस्था और स्तनपान
- गर्भावस्था
- Unsafe Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy
- स्तनपान
- Unsafe Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
रिपोर्ट किए गए दुष्प्रभाव
- Nasopharingitis
- Constipation
- Gastroenteritis
- Urinary tract infections
- Hypoglycaemia
- Diarrhea
बॉक्स्ड चेतावनियाँ
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain) Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL Risk factors include…
प्रतिसंकेत
- Hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients in the product
- Metabolic acidosis, including diabetic ketoacidosis
- Severe renal impairment (eGFR <30 mL/min/1.73 m2), ESRD, or dialysis
किन्हें सावधानी रखनी चाहिए
- Serious hypersensitivity reactions, (eg, angioedema) in patients treated with empagliflozin reported postmarketing; discontinue therapy and treat promptly if it occurs per standard of care
- There have been reports of acute pancreatitis, including fatal pancreatitis; if pancreatitis suspected, promptly discontinue
- Heart failure observed with 2 other DPP-4 inhibitors; consider risks and benefits in patients with known risk factors for heart failure; monitor for signs and symptoms
गर्भावस्था या स्तनपान, किडनी या लिवर के रोग, एलर्जी और आप जो भी अन्य दवा या सप्लीमेंट लेते हैं, उसके बारे में अपने फार्मासिस्ट या डॉक्टर को बताएँ।
Pro+ सदस्यों के लिए
पूरा पेज खोलें
Empagliflozin-linagliptin-metformin का पूरा मोनोग्राफ खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें: खुराक, गर्भावस्था और स्तनपान, दुष्प्रभाव, चेतावनियाँ और सभी इंटरैक्शन।
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
वेब पर Pro+ को 14 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।
इसी वर्ग की अन्य दवाएँ
अक्सर पूछे जाने वाले प्रश्न
What is Empagliflozin-linagliptin-metformin used for?
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Empagliflozin-linagliptin-metformin?
Nasopharingitis, Constipation, Gastroenteritis, Urinary tract infections, Hypoglycaemia, Diarrhea. Serious warning: Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress,…
Can Empagliflozin-linagliptin-metformin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy Breastfeeding: Unsafe. Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
What does Empagliflozin-linagliptin-metformin interact with?
MediHelp does not list a checked interaction for Empagliflozin-linagliptin-metformin yet. Always tell your pharmacist about every medicine you take.
MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर
MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।
